Multiple Sclerosis Flashcards

1
Q

what is MS?

A
  • a demyelinating disease
  • Affects white matter of brain – myelin stripped from nerve axons
  • When myelin is damaged, this interferes with messages between the brain and other parts of the body
  • For some people, MS is characterised by periods of relapse and remission while for others it has a progressive pattern
  • For everyone, it makes life unpredictable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

which people are most affected by MS?

A

Affects young women
- Chronic relapsing-remitting form of disease at first, that progresses to chronic form

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is the incidence of MS?

A

The most common disabling, neurological condition affecting young adults
- >130,000 people in the UK affected
- Ratio of disease in women and men
- Association with HLA class II MHC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are the 2 key risks for MS susceptibility?

A
  1. Link between HLA type and susceptibility to disease
  2. Link between sex and susceptibility to disease

For MS, 5x more likely to get if you have HLA-DR2 and are female

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

why do women have a greater risk of autoimmunity than men?

A

Women have stronger immune systems
- There is hormonal influence on 158 genes that control the immune system – oestrogen promotes inflammatory responses
- Women have XX chromosomes – many genes controlling inflammation are on the X chromosome
- Second X chromosome is not fully inactivated – women get two shots of inflammation
- Women respond better to infection as they are needed for species survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

is genetics the only risk factor for MS?

A
  • If one twin develops MS, 1/3 chance the other will develop the disease
  • genetics isn’t the only factor
  • > 100 distinct genetic regions have been identified as being associated with multiple sclerosis through GWAS,
  • SNPs make up 1/3 genetic component of MS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

how did MS spread across the world?

A

Looked at ancient genomes from ancestor:
- Epicentre of MS in northern Europe which spread to north America
- Steppe herders migrated and settled in northern Europe, who had genetic predisposition to MS after fighting off a plague-like disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what are the key clinical brain symptoms of MS?

A
  • CNS inflammation due to demyelination - high water retention in the brain - water disrupts brain tissues
  • periventricular lesions
  • injection of gadolinium dye into bloodstream of patient before MRI, this shows breakdown of the BBB as the dye can enter the brain - blood vessels have been compromised
  • BBB breakdown means immune cells can enter the brain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How do gadolinium-enhancing lesions effect the brain of an MS patient?

A

Axial T1-weighted scans after injection of Gadolinium, measured on a monthly basis:
- In one patient, lesions show all over the brain
- Every time a lesion happens, there is irreversible damage to nerve axons at that site – builds up to chronic progressive form of disease
- with every lesion, there is loss of nerve axons, so this part of brain is unable to function properly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is the hallmark pathology of the brain in MS?

A

Jean Martin Charcot showed fibrotic plaques in brain of MS patient:
- He correlated these plaques to the triad of MS symptoms:
impact on vision, balance and spleech

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is white matter/myelin?

A

white matter – nerve axons (cell in middle)
- Myelin sheath is affected in MS
- Myelin is one cell that squeezes its membrane together and wraps around axon multiple times
- Fatty myelin sheath wrapped around by oligodendrocyte
- an oligodendrocyte can wrap around numerous axons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what are the distinct patterns of MS disease?

A

Relapsing-remitting form is most common:
- Difficult to diagnose MS – can look like clinically isolated symptoms so doctors may send away as a one-off incident – if patient comes back with second symptom, a lot of damage by then has been done – need to treat as early as possible

Chronic form:
- build-up of lesions and damage, patients lose ability to function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

how are immune cells implicated in MS?

A

Immune cells cross blood- brain barrier and infiltrate parenchyma
- Immune cells then contribute to demyelination and axon loss
- Activation of myelin-reactive T cells – promote activation of microglia in brain and macrophages entering brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is the glia limitans?

A

a membrane formed by combo of basement membrane tissue and foot processes from astrocytes
- Astrocyte project feet which merge to form glia limitans
- T cell needs to go through blood vessels and glia limitans to enter brain – difficult to infiltrate brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

why is the brain distinct from other tissues?

A

Brain is unique as it is difficult to enter
- Brain is protected by blood vessels and the glia limitans

Protected from:
- Physical injury by the skull and associated tissues
- Blood-borne pathogens by the blood brain barrier (BBB)
- Cells and antibodies of the immune system by the BBB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are perivascular cuffs?

A

around the blood vessel is a collection of lymphocytes and neutrophils
- These inflammatory cells queue up to cross the glia limitans into parenchyma of brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what is the mouse model of MS?

A

experimental autoimmune encephalomyelitis mice - EAE pathology identical to human MS patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

can the stipping of myelin be seen in brain?

A

fatty luxol fast blue stains myelin in brain
- active demyelinating centre can be seen, where myelin is stripped away

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what happens if the spinal cord is demyelinated?

A

Spinal cord carries motor messages to limbs
- if a massive part of spinal cord is demyelinated, motor messages will not reach the limbs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what causes myelin loss in MS?

A

Myelin loss is due to antibody deposition on sheath, which activates microglia
- Microglia attach to the myelin sheath and strip it away
- Microglia wraps around nerve axon to remove myelin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what immune cells are contained in MS plaques?

A

Plaques contain macrophages:
- macrophage contains vesicles full of fat
- White encapsulated spots are fat globules in macrophages from myelin
- macrophage strips away myelin, breaks it down and stores the lipids in vesicles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

how does the loss of myelin by immune cells affect nerve conduction?

A

Metabolic change in neuron due to loss of myelin:
- ROS and NOS damage mitochondria and stop ion flow up the nerve axon
- Myelin sheath designed for saltatory conduction – action potential (AP) jumps from node to node
- Loss of myelin means jumping APs cannot occur – slow AP propagation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

why does loss of myelin lead to impaired saltatory conduction?

A

Sodium channels in membrane become over expressed to compensate for slowed AP propagation:
- Causes glutamate accumulation in nerve axon
- Leads to nerve axon dividing = transection of nerve axon
- In the demyelinated region, nerve axon swells and breaks away
- Cut nerve axons which cannot recover

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

how can transected axons be studied?

A

Confocal image of axonal changes in active MS lesion
- used non-phosphorylated neurofilament stain - shows nerve axons to see where they have been transected
- can count number of transected axons in different lesions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

how abundant are transected axons in MS lesions?

A

In an active lesion, there are over 11,000 transected axons in a square mm of CNS tissue – loss of function
-As number of active lesions build, there is accumulation of axonal function loss

fMRI shows some synaptic plasticity to allow the brain to recover function – but this doesn’t occur in parts of brain where axons have been lost

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

what immune cells were discovered in the EAE model to drive MS?

A

CD4 T cells cause this disease:
- Loss of CD4 from EAE model means the mouse can’t develop MS

Tregs also control this disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

how can CD4 T cells be studied in MS?

A

Immunise rat with MS antigen, myelin basic protein (MBP)
- MBP-specific CD4 T cells will be generated, which can be isolated
- retrovirally transduce the T cells with GFP
- transfer the MBP-specific CD4 T cells into naive rats
- over time, rats develop MS-like symptoms at day 3 - generation of EAE model
- imaged blood vessels of EAE model: by day 3, millions of cells migrating into the parenchyma of brain, lining up to pass through blood vessel and glia limitans into brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

what are the disease symptoms of the EAE model?

A

Clinical signs appear d3
Mean EAE grade 1 at d3
Disease peak, grade 3, at d4
Disease resolves d8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

what enables leukocytes to enter the brain?

A

leukocyte emigration and inflammation, driven by selectins and integrins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

what integrin controls CNS T cell migration?

A

The integrin that required for entry into CNS is different to blood vessels around rest of body
- In the body it is LFA1
- In brain it is a4b1 (VLA-4)
- a4b1 can be specifically targeted

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

how can VLA-4 be specifically targeted to inhibit CNS T cell migration?

A
  • Injection of LFA-1 antibody does nothing as it is body specific
  • Injection of VLA-4 antibody (natalizumab) stops leukocytes entering brain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

why is natalizumab limited in MS treatment?

A

Blocking VLA-4 has downsides:
- We need T cells to enter the brain to prevent infection
- so blocking this migration may lead to brain infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

which T cells have been implicated in MS pathology via the EAE model?

A

Th17 and Th1 cells can promote MS pathology:
- Stimulate cells in vitro with IL-23 – promotes TH17 generation
- Stimulate cells in vitro with IL-12 – promotes Th1 generation
- Transfer these cells into naïve mouse – both TH1 and TH17 cells can cause disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

what do Th1 (IL-12) and Th17 (IL-23) cells cause in MS?

A

T cells specific for PLP 139-151 (myelin proteolipid protein) can be polarized towards Th1 and Th17 in vitro
- IL-23 supports cells making IL-17 and interferon-gamma
- Both IL-12 and IL-23 cells cause spinal cord disease
- IL-23 cells cause more severe optic neuritis
- IL-23 cells cause severe neutrophilic infiltration

35
Q

which immune cells and their cytokines initiate EAE?

A

Th1 and Th17 cells have both been invoked as causing MS:
- However, T cells deficient in INF-gamma or IL-17 are still encephalitogenic (disease-causing)
- GM-CSF is also induced by IL-23 and IL-12 cells
- T cells deficient in GM-CSF failed to induce EAE
- GM-CSF is crucial for both Th1 and Th17 cells in EAE

36
Q

why is immune regulation critical in MS?

A

TCR transgenic mice:
- Mouse expresses one TCR specific for brain protein e.g. MBP
- Normally, mice lack disease because Tregs are in the brain to suppress Th1/Th17 activation
- If Th1/Th17 are activated, they cause lesions

Tregs are critical in preventing MS

37
Q

how was the role of Tregs in MS shown?

A
  • K/O of RAG gene in Tg4 transgenic mice means that these mice do not make FOXP3+ Tregs
  • These mice develop spontaneous EAE as they lack Tregs
  • RAG-positive mice remain disease-free throughout life
  • without RAG and thus without FOXP3+ Tregs, the mice develop EAE around week 12

If the RAG K/O mice have Tregs transferred back in which express the MBP-specific TCR, these mice are protected from disease

Tregs have major impact on disease susceptibility

38
Q

what are the regulatory mechanisms of Tregs?

A
  • Treg cells control homeostatic expansion
  • Treg cells produce anti-inflammatory cytokines such as TGFb and IL-10
  • Treg cells moderate dendritic cell activation via IL-10
  • upregulate inhibitory receptors to dampen T cells
39
Q

how does an MS relapse occur?

A

Under infection of upper respiratory tract, Tregs are recruited to dampen down the immune response at the lung, enabling MS to relapse in the brain as Tregs are no longer present
- Tregs overriden by infection

40
Q

how are comorbidities involved in MS?

A

campath antibody (blocks T cells, B cells and monocytes (pan-leukocyte antibody)) can be used to treat RA and MS
- worked well for RA but caused poor infections
- 50% of MS patients treated with CAMPATH had reduction in MS but developed Graves disease

41
Q

how are Tregs impacted in MS?

A

Tregs in people with MS are less effective than in healthy people

42
Q

what are the key conclusions of Tregs in MS?

A
  • FoxP3 expressing natural Treg cells protect myelin TCR transgenic mice from spontaneous disease
  • IL-10 maintains self-tolerance in the Tg4 TCR transgenic mouse model
  • IL-10 is required for function of FoxP3 Treg in suppressing EAE
43
Q

key conclusions from lecture:

A

Animal models have revealed much of what we currently understand about multiple sclerosis

MS represents the distinct but overlapping mechanisms of inflammation and neurodegeneration

Future therapies must target both auto- immune and neurodegenerative processes

44
Q

what is meant by EBV causality of MS?

A

Causality: some individuals who have developed MS after EBV infection would not have developed MS if they had not been infected with EBV

45
Q

why is it difficult to confirm that EBV causes MS?

A

Difficult to test unequivocally when such a high proportion of population are EBV seropositive – 95% of population in UK ar EBV seropositive
- Infection alone is clearly insufficient, as the overwhelming majority of EBV-infected individuals never develop MS

46
Q

what evidence suggests that EBV causes MS?

A
  • EBV infection manifesting as infectious mononucleosis (IM) in adolescents and young adults is a risk factor for MS
  • encountering EBV later in life is a clearer risk factor for MS
  • There are elevated serum antibody titers against EBV nuclear antigens (EBNAs) in MS
  • People who remain EBV seronegative have little chance they will get MS
  • Presence of EBV in MS demyelinated lesions where EBV EBER denotes EBV encoded small nuclear RNA
47
Q

how is EBV and age linked with MS?

A

If someone gets EBV as a child, moderate MS risk: Getting EBV early can protect from MS, but link between MS and EBV in children is stronger than in adults

If someone develops IM later in life, higher incidence of MS

People develop MS between 20-40 years of age
- Temporal association in those who are susceptible to MS if they develop IM – IM enhances likelihood of MS

48
Q

what was the DDSR (Department of Defense Serum Repository) meta-analysis case for MS?

A

Of 10 million, 1000 developed MS
- 800/801 available MS samples were EBV seropositive
- 32/33 individuals who were EBV negative at the beginning and later developed MS ended up being EBV seropositive – is this enough to say a 32x increased risk?

49
Q

what is the neurofilament light chain evidence for EBV and MS link?

A
  • Serum levels of neurofilament light chain (sNfL) were shown to increase up to 6 years before onset of MS
  • sNfL levels in individuals who were EBV-negative at baseline and went on to develop MS were similar to those of non-MS controls before and around the time of EBV infection but increased after EBV infection
  • Another study found a lack of correlation of NFL with progression of MS
50
Q

how might EBV cause MS?

A
  1. EBV CNS invasion with direct or indirect viral injury to oligodendrocytes
  2. Upregulation of EBV-activated autoreactive T and B cells that migrate to the CNS, cause antiviral immune pathology and bystander injury to CNS tissue
  3. Molecular mimicry in which EBV infection induces antibody or T cell responses that are directed against viral antigens or epitopes but that cross-react with myelin or other CNS antigens
51
Q

does EBV cause injury to brain tissue?

A

Can find EBV in MS brain tissue, but in B cells and plasma cells, not in neurons, oligodendrocytes and astrocytes - no evidence for direct injury to the brain by EBV

Another MS-like disease in macaques – primate herpes virus similar to EBV causes this – this virus can be seen in demyelinating lesions

52
Q

how is molecular mimicry implicated for EBV and MS?

A

IgG in CSF of MS (oligoclonal bands) has been used for diagnosis of the disease
- In MS, IgG is reactive to viral, e.g. EBNA-1, bacterial and self-antigens
- plasmablasts from CNS have antibodies specific for EBV antigens especially the TF EBNA-1
- Evidence that these cells undergo affinity maturation: the resulting antibodies then cross-react with the CNS glial cell adhesion molecule
- Crossreactivity of EBNA-1 and glial protein
- Mimicry is promoted by post-translational modification(SerPi) of the Glial CAM molecule

53
Q

how may B cells promote molecular mimicry in MS and drive disease?

A

EBV-specific B cells receive T cell help in brain – affinity maturation and class-switching
- Somatic hypermutation provide antibodies that can cross-react against self antigen
- Worse infiltration in MS-like mice induced by EBNA1 peptide
- Implies that induction of immune response to EBNA1 peptide can promote worse disease

54
Q

how are T cells implicated in MS molecular mimicry?

A

millions of different peptides can weakly activate TCR - TCRs don’t just recognise one peptide epitope, they can cross-react
- Peptides from EBV, CMV, HPV could give strong immune response to T cell clones specific for MBP
- TCR cross-reactivity of self-reactive T cells is highly likely – fits with EBV hypothesis
- But this could also be triggered by any other pathogen e.g. flu, bacteria

55
Q

how have EBV-specific T cells been used to treat MS in a trial?

A

5 patients with SPMS (chronic progressive) and 5 with PPMS (even worse MS) – very poorly patients
- Made EBV-specific CD8 T cell cultures with patient own blood and fed back into patients
- 7/10 patients improved

56
Q

how can therapies target B cells in MS?

A

Killing B cells in MS patients in CNS causes improvement
- anti-CD20 can cause fewer new enhancing lesions seen in MRI - suppress inflammation associated with MS
- Remove pools of EBV infected B cells or deplete B APCs for CNS specific T cells or alter the profile of B cells entering the CNS (inflammatory to anti-inflammatory)

57
Q

why isn’t EBV the only factor for MS?

A

Other major pre-disposing factors: gender (female>male more liley to develop MS), MHC type (HLA-DL2 closely linked with MS), 200 another genes shown via GWAS have a link, 30 of these SNPs are in MHC, other environmental factors e.g. smoking, obesity, lack of vitamin D, infection

58
Q

is EBV linked to MS?

A

EBV is clearly linked to MS, and accumulating data suggest it is an early factor in the initiation of disease.
- Plausible biological mechanisms for EBV’s pathogenic role in MS have now been elucidated, but a universal unifying mechanism has not yet been identified

59
Q

what are novel therapies are used for MS?

A
  • cytokine therapy e.g. targeting cytokines or cytokine receptors
  • targeting lymphocyte migration e.g. Natalizumab (anti-VLA-4), FTY720 to inhibit T cell migration
  • epitope mimetic - similar to MBP and injected into patients
  • antigen-specific approaches
60
Q

what is the ideal future therapy for MS?

A

Target antigen
- Mimic what happens in allergy via allergic desensitisation
- Give people the target antigen that is causing the disease to switch off the disease
- enables specific disease targeting, with fewer side effects

61
Q

what are the current autoimmune therapies and their risks?

A
  • anti-TNF - TNF is required for myelination in the brain, so blackbox warning for use in MS
  • anti-CD52 - wipes out leukocytes, stops MS but can cause Graves in 20-30% patients
  • anti-CD3 can induce toxic shock syndrome
  • anti-CD20 depletes B cells
  • anti-VLA4 increases risk of Progressive multifocal leukoencephalopathy (PML)
  • FTY720 can cause heart block, skin cancer
  • anti-IL-6R - increased infections, neutropenia
62
Q

what is Progressive multifocal leukoencephalopathy (PML)?

A

PML is caused by the reactivation of a common virus in the central nervous system of immune-compromised individuals
- Polyomavirus JC is carried by the majority of people and is harmless except among those with lowered immune defences
- Stopping immune surveillance of brain, e.g. anti-VLA4, can lead to reactivation of this virus

63
Q

what is allergic desensitisation?

A

Allergic desensitisation – inject patient with allergen over 2 years – switches off immune response to the allergen
- Can be dangerous as mast cells coated with IgE can induce anaphylactic shock and death
-This process tends to be done in hospital setting

64
Q

has desensitisation worked in MS?

A

Tried to do the same with myelin oligodendrocyte protein in primate model
- Created new disease – induced antibodies against MOG which made disease worse

Shouldn’t use in tact antigen – need to focus on CD4 T cell epitopes as they won’t induce cytotoxic T cells
- T cell epitopes have random conformation so are not good at activating B cells

65
Q

why does antigen-targeting therapy aim to switch of CD4 T cells?

A

All disease mechanisms of MS are controlled by CD4 T cells
- They control B cells – class-switching, affinity maturation
- They are required for macrophage/microglia activation
- They are required for inducing CD8 cell differentiation

If CD4 T cells are switched off, the immune response can be controlled

66
Q

what is bystander suppression?

A

the induction of tolerance to antigen A within a tissue that spreads to suppress the immune response to antigens B, C, D etc from the same tissue

67
Q

how can bystander suppression be induced in MS?

A

In MS, target antigen is myelin antigens e.g. MBP, MOG
- Need to induce immune regulation which has bystander effect to other MS antigens
- Peptide fragments from myelin have the same effect
- Can use one epitope from a protein to switch of immune response to the same protein, or to another protein

68
Q

what is an apitope?

A

Not all T cell epitopes induce tolerance
= Peptides must mimic naturally processed epitopes
- Peptides must be soluble to reach steady-state dendritic cells in lymphoid organs

Apitope is a peptide that can bind MHC without antigen processing
- Antigen processing-independent T cell epitope = apitope

69
Q

how can apitopes be used to tolerise T cells?

A

Steady state immature DCs have peptide receptor for MHC at surface
- Injection of apitope peptide that can bind MHC in right conformation – peptide won’t bind MHC on B cells or macrophages, but will bind MHC on steady state dendritic cells
- Steady state DCs have low levels of co-stim molecules
- Differential TCR signalling without CD28 signal

70
Q

can apitopes impair T cell function?

A

Repeating apitope dosing can switch off immune response
- Tg4 mouse carries TCR specific for MBP
- This mouse develops spontaneous demyelination – grade 3, so both hind lumbs of mouse are paralysed
- 6 doses of apitope – at week 6 of age, mice are protective for life from disease
- Escalating dose of antigen: the higher the dose, the more anergic the T cells become – the T cells are present, but are no longer responsive to the antigen
- Increasing levels of anergy

71
Q

what are the features of apitope-induced anergic T cells?

A

Stimulation of anergic T cells in vitro – start releasing IL-10
- Tr1 are foxp3-, IL-10 producing Tregs
- The higher the apitope dose, the more suppressive these CD4 T cells cells become

72
Q

overall model of immunotherapy with apitopes:

A

When a soluble peptide is injected, it is picked up by steady state DC
- Naïve or effector CD4 cell upregulates inhibitory receptors e.g. CTLA-4, TIM-3, and switch TFs – change from TBET, GATA3 to MAF and NFIL3 to drive generation of IL-10 and become Tr1 cells

73
Q

how do apitope-derived Tr1 cells induce bystander suppression?

A

Tr1 cell specific for antigen A releases IL-10, which downregulates co-stim molecule expression on APCs
- APC presenting antigens A-E,
- Tr1 contacts APC which is expressing antigens from the brain – the Tr1 downregulates the presenting machinery, especially co-stims, on the APC
- This means that new T cells are now switched off, because they are only getting signal 1, and not signal 2 – bystander induction of anergy

74
Q

how do tolerised CD4 cells adapt to repeated apitopes?

A

Tolerised CD4 cells become Tr1 cells which form immune synapse with pathogenic Th1 cells:
- Molecular machinery such as Zap70 migrate into immune synapse of Th1 cell
- They don’t migrate in the tolerised cell
- Membrane proximal block in cell signalling – ubiquitin-ligase ubiquinates signalling machinery such as Zap70 at synapse of Th1 – tolerised cell blocks cell signalling of Th1

75
Q

how do Tr1 cells produce IL-10 with such little TCR signalling?

A

In a naïve T cell activated by antigen – IL-2, IL-3, NR4A are transcribed

In a tolerised cell – these genes are switched off, and there is an IL-10, LAG3, CMAF signature switched on
- Whole genome epigenetics of tolerised cells with repetitive stimulation
- IL-10 gene has a nearby DNAse hypersensitive site where chromatin is open in resting cells
- the sequence of this site binds Ets and RUNX
- This modification keeps the IL-10 gene unstable/relaxed, so low level of signalling can lead to transciption of IL-10

76
Q

what antigens are in MS?

A

MS is an immune response to myelin e.g. MBP, PLP and MOG

77
Q

what happens if MS antigens are repetitively given to mice?

A

First tested antigen cocktail ATX-MS-1467 in mouse with human HLA-DR2 and TCRs from MS patient – TCR specific for MBP
- This mouse developed MS-like disease
- Give peptide 3 times – blocked disease progression
- When disease is suppressed by peptide, this blocks IL-2, IFNy, IL-17 production by T cells, and switching to IL-10 production

78
Q

has ATX-MS-1467 been successful in clinical trials?

A

Clinical trial – 43 patients with 2 treatment arms – dose escalation of peptide into skin every 2 weeks
- Measured Gde enhancing MRI to look for CNS inflammation
- When reaching optimal dose – peptide 5 times – there is an 80% reduction in lesions in these patients,
- lasts for a month and then disease comes back
- In humans, peptides need to be continually given

70% reduction in lesion volume in phase 2 study
- Improvement in cognitive score of patients
- Suppressing inflammation in CNS improves cognition

79
Q

Is treatment with ATX-MS-1467 safe and well tolerated?

A

Safety data from 68 patients shows no evidence of unexpected safety signals with the majority of adverse events relating to the subjects’ underlying disease or minor injection site reactions

80
Q

what is the overall conclusion for apitope therapy?

A

Proteins can be replaced with apitopes, representing T cell epitopes, for effective desensitization of cells causing allergy, autoimmunity and other unwanted immune responses
- Apitope therapy is proven in a range of immune pathologies e.g. currently being done in Type 1 diabetes
- The use of apitopes has given insight into the mechanism and molecular changes associated with specific immunotherapy
- Specific immunotherapy is a targeted approach treating the underlying disease pathology by selectively reinstating immune tolerance rather then global immune suppression

81
Q

therapies which target cytokines:

A

anti-TNF: neutralises TNFa, used in RA, slows joint damage

anti-IL-6R: interferes with IL-6 signalling, reduces RA symptoms

anti-IL12/23: prevents Th1 and Th17 differentiation, used in psoriasis and Crohn’s, reduced disease in 60% patients

82
Q

therapies which target T cell function:

A

CTLA-Ig: comperes with CD28 for CD80/86, reduces RA symptoms

LFA3-Ig: deletes all leukocytes, decreased MS relapse rate

anti-CD3: anergy/apoptosis, promotes Tregs to secrete TGFb, mantains beta-cell function in type 1 diabetes phase II trial

anti-CD25: inhibits activated T cells, reduction in MS MRI activity

83
Q

therapies which target B cell function:

A

anti-CD20: inhibits autoantibody production, limits B cell APC function, reduces ectopic tertiary lymphoid structures
- reduces brain lesions in MS
- retains beta cell function in type 1 diabetes

anti-CD22 reduces disease activity in SLE